Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current therapy of multiple myeloma.

Robert A Kyle1

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Mayo Medical School Rochester, Minnesota 55905, USA.

Internal Medicine (Tokyo, Japan)
|April 4, 2002
PubMed
Summary

Treatment decisions for multiple myeloma depend on patient age and transplant eligibility. Autologous stem cell transplantation is recommended for younger patients, though challenges remain in eradicating cancer cells.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

James Allison and Cancer Immunotherapy.

Mayo Clinic proceedings·2020
Same author

Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma.

Blood advances·2020
Same author

The role of bone marrow biopsy in patients with plasma cell disorders: should all patients with a monoclonal protein be biopsied?

Blood cancer journal·2020
Same author

Monoclonal Gammopathy of Undetermined Significance: Indications for Prediagnostic Testing, Subsequent Diagnoses, and Follow-up Practice at Mayo Clinic.

Mayo Clinic proceedings·2020
Same author

Razi: Critical Thinker, and Pioneer of Infectious Disease and Ophthalmology.

Mayo Clinic proceedings·2020
Same author

Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.

Clinical lymphoma, myeloma & leukemia·2020

Area of Science:

  • Hematology
  • Oncology
  • Stem Cell Transplantation

Background:

  • Multiple myeloma diagnosis requires careful consideration for treatment initiation.
  • Patient age is a critical factor in determining therapeutic strategies.

Purpose of the Study:

  • To review current treatment approaches for multiple myeloma.
  • To discuss the role and challenges of stem cell transplantation.
  • To explore novel therapeutic agents and supportive care.

Main Methods:

  • Review of existing literature on multiple myeloma treatment.
  • Analysis of autologous and allogeneic stem cell transplantation efficacy and risks.
  • Discussion of emerging drug classes and supportive management strategies.

Main Results:

  • Autologous peripheral blood stem cell transplantation is a viable option for patients under 70.
  • Significant challenges persist in eradicating multiple myeloma cells during transplantation.
  • Allogeneic transplantation is currently associated with high mortality.
  • Nonmyeloablative approaches show promise.
  • No clear superiority of alkylating agent combinations over melphalan and prednisone was found.
  • Thalidomide and prednisone maintenance strategies are under investigation.
  • Novel agents targeting various pathways are emerging.

Conclusions:

  • Treatment selection for multiple myeloma requires individualized assessment.
  • Stem cell transplantation, particularly autologous, is a key consideration for eligible patients.
  • Ongoing research into novel agents and supportive care aims to improve outcomes and manage complications.

Related Experiment Videos